• Eman A Toraih, Rami M Elshazli, Mohammad H Hussein, Abdelaziz Elgaml, Mohamed Amin, Mohammed El-Mowafy, Mohamed El-Mesery, Assem Ellythy, Juan Duchesne, Mary T Killackey, Keith C Ferdinand, Emad Kandil, and Manal S Fawzy.
• Department of Surgery, School of Medicine, Tulane University, New Orleans, LA.
• J. Med. Virol. 2020 Nov 1; 92 (11): 2473-2488.

BackgroundCoronavirus disease-2019 (COVID-19) has a deleterious effect on several systems, including the cardiovascular system. We aim to systematically explore the association of COVID-19 severity and mortality rate with the history of cardiovascular diseases and/or other comorbidities and cardiac injury laboratory markers.MethodsThe standardized mean difference (SMD) or odds ratio (OR) and 95% confidence intervals (CIs) were applied to estimate pooled results from the 56 studies. The prognostic performance of cardiac markers for predicting adverse outcomes and to select the best cutoff threshold was estimated by receiver operating characteristic curve analysis. Decision tree analysis by combining cardiac markers with demographic and clinical features was applied to predict mortality and severity in patients with COVID-19.ResultsA meta-analysis of 17 794 patients showed patients with high cardiac troponin I (OR = 5.22, 95% CI = 3.73-7.31, P < .001) and aspartate aminotransferase (AST) levels (OR = 3.64, 95% CI = 2.84-4.66, P < .001) were more likely to develop adverse outcomes. High troponin I more than 13.75 ng/L combined with either advanced age more than 60 years or elevated AST level more than 27.72 U/L was the best model to predict poor outcomes.ConclusionsCOVID-19 severity and mortality are complicated by myocardial injury. Assessment of cardiac injury biomarkers may improve the identification of those patients at the highest risk and potentially lead to improved therapeutic approaches.© 2020 Wiley Periodicals LLC.

24 keywords...

hide…